Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative therapeutics in areas of unmet medical need. Its work is concentrated in virology, including HIV treatment and prevention and a curative therapy for hepatitis C, with further programmes in oncology and inflammatory diseases. The company invests billions of dollars annually in research and development.

More than 17,000 employees work for Gilead across operations in over 35 countries. Scientific and commercial work spans drug discovery and development through to biopharmaceutical commercialisation, with technical domains covering virology, oncology, inflammation and immunology. The oncology and inflammation portfolios have been advanced through both internal innovation and strategic acquisitions.

Gilead states a commitment to addressing global health challenges and to dismantling health inequities. It expands treatment access through partnerships, pricing initiatives and patient-assistance programmes in multiple countries.